Oncology Knowledge into Practice Podcast Liberum IME

In today's episode, we welcome Dr. Sandip Patel, who is a Professor of Medical Oncology at the University of California, San Diego, to discuss the evolution of molecular profiling technology, focusing on how next-generation sequencing can help support patients with advanced thyroid cancer, but also how to integrate molecular profiling into clinical practice.



Learning Objective(s):

After completing this educational activity, learners will be able to discuss precision medicine and new technologies, including liquid biopsy

Funding Information:

This independent educational activity is supported by an educational grant from Eli Lilly. The educational content has been developed by Liberum IME in collaboration with an independent steering committee; Eli Lilly had no influence on the content of this educational activity.

Accreditation:

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the ACHL and Liberum IME. ACHL is accredited by the ACCME to provide continuing medical education for physicians.

The Academy for Continued Healthcare Learning (ACHL) designates this enduring material for up to 0.25 AMA PRA Category 1 Credits™. Physicians should claim credit commensurate with the extent of their participation in the activity.

The American Medical Association (AMA) has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 Credit™ to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMEC®s) should contact the UEMS at mutualrecognition@uems.eu

The content for this activity was developed independently of the ineligible companies. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantors.

This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

Faculty disclosures

Dr. Sandip Patel:

Scientific advising (Ongoing): Amgen, AstraZeneca, BeiGene, Bristol-Myers Squibb, Certis, Eli Lilly, Jazz, Genentech, Illumina, Merck, Pfizer, Rakuten, and Tempus

Institutional research funding (Ongoing): Amgen, AstraZeneca/MedImmune, Bristol-Myers Squibb, Eli Lilly, Fate Therapeutics, Gilead, Iovance, Merck, Pfizer, Roche/Genentech, SQZ Biotechnologies"

Other disclosures

Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

In today's episode, we welcome Dr. Conor Steuer, which is Associate Professor at the Department of Hematology and Medical Oncology at Emory University School of Medicine in Atlanta, USA, to discuss adaptation of thyroid cancer guidelines to local care settings. We touch on strategies for guideline implementation and how to overcome potential barriers.

Target Audience:

Oncologists, pathologists and other HCPs involved in the diagnosis of RET and TRK cancers, with a focus on community practitioners.

Learning Objective(s):

After completing this educational activity, learners will be able to:

• Recall thyroid RET and TRK fusion-positive cancer diagnosis and relevant genomic testing guidelines, and identify ways to adapt the guidelines to local settings

• Review the organization of care and strategies for more efficient care delivery

Funding Information:

This independent educational activity is supported by an educational grant from Eli Lilly. The educational content has been developed by Liberum IME in collaboration with an independent steering committee; Eli Lilly had no influence on the content of this educational activity.

Accreditation:

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the ACHL and Liberum IME. ACHL is accredited by the ACCME to provide continuing medical education for physicians.

The Academy for Continued Healthcare Learning (ACHL) designates this enduring material for up to 0.25 AMA PRA Category 1 Credits™. Physicians should claim credit commensurate with the extent of their participation in the activity.

The American Medical Association (AMA) has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 Credit™ to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMEC®s) should contact the UEMS at mutualrecognition@uems.eu

The content for this activity was developed independently of the ineligible companies. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantors.

This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

Faculty disclosures:

Conor Steuer

Advisory Board/Steering Committee (Ongoing): Daiichi

Advisory Board (Former): Caris, Merck, Mirati, Novocure, Sanofi/Regeneron

Other disclosures

Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

Developments in precision medicine have led to a paradigm shift in the management of advanced thyroid cancer. The ESMO Guidelines Committee recently developed a new clinical practice guideline on the use of systemic therapy in this setting.

This episode offers guideline insights into the applications recently approved therapies that have been approved by the FDA and/or the EMA, including cabozantinib, selpercatinib, pralsetinib, and entrectinib. It also provides data updates of previously approved therapies and how guidelines have been adapted accordingly. To answer questions on the 2022 ESMO Clinical Practice Guideline update, we have invited Dr. Ahmad Awada to join us. He is Head of the Oncology Medicine Department at Jules Bordet Cancer Institute Brussels, Belgium.


Target Audience:
Oncologists, pathologists and other HCPs involved in the management of advanced thyroid cancer, with a focus on community practitioners.

Learning objectives:
After completing this educational activity, learners will be able to:


Recall thyroid RET and TRK fusion-positive cancer diagnosis and relevant genomic testing guidelines, and identify ways to adapt the guidelines to local settings
Discuss precision medicine and new technologies, including liquid biopsy
Review the organization of care and strategies for more efficient care delivery

Funding information:
This independent educational activity is supported by an educational grant from Eli Lilly. The educational content has been developed by Liberum IME in collaboration with an independent steering committee; Eli Lilly had no influence on the content of this educational activity.


Disclosures
Dr. Ahmad Awada declares the following financial relationships from the past 24 months: Speaker fees: Amgen, AstraZeneca, Bayer, Daiichi Sankyo, Eisai, Genomic Health, Ipsen, Leo Pharma, Eli Lilly, Merck, MSD, Novartis, Pfizer, and Seattle Genetics.

Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
ACHL requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any ineligible companies. All relevant financial relationships have been mitigated prior to this activity.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires its speakers to disclose that a product is not labeled for the use under discussion.
Discussion of Off-Label, Investigational, or Experimental Drug Use: N/A

In today’s episode, we welcome expert Oncologist Dr. Claire Arthur and expert Endocrinologist Dr. Sarimar Agosto Salgado to discuss the challenges they have encountered and strategies that they have implemented to improve multidisciplinary collaboration in the management of patients with thyroid cancer and continued integration of precision medicine approaches.

References

1. Fenton ME et al. Variability in thyroid cancer multidisciplinary team meeting recommendations is not explained by standard variables: Outcomes of a single centre review. J Clin Med 2021;10:4150

2. Horgan D et al. Tackling thyroid cancer in Europe—The challenges and opportunities. Healthcare 2022;10:1621

3. Mehra S et al. Improving the quality of thyroid cancer care: How does the Thyroid Cancer Care Collaborative cross the Institute of Medicine’s Quality Chasm? Thyroid 2014;24:615–624

Target Audience:

Oncologists, pathologists and other HCPs involved in the diagnosis of RET and TRK cancers, with a focus on community practitioners.

Learning Objective:

1. Recall thyroid RET andTRK fusion-positive cancer diagnosis and relevant genomic testing guidelines and identify ways to adapt the guidelines to local settings

2. Discuss “precision medicine” and new technologies, including “liquid biopsy”

3. Review the organisation of care and strategies for more efficient care delivery

Funding Information:

This episode is supported by an educational grant from Eli Lilly, who have had no influence on the content or choice of faculty.

Disclosures:

Dr Sarimar Agosto Salgado: 

- Speaker: Lilly

- Advisor: Exelisis, Lilly, Blueprint medicines, Eisai

Dr Claire Arthur

Dr Claire Arthur has no relevant disclosures against this module

Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

In today’s episode, we welcome Dr. Antonio Matrone, an endocrinologist at the University of Pisa, to discuss the many factors involved in treatment decision-making and strategies for the management of patients with advanced thyroid cancer where an oncogenic driver has been identified.

References


Matrone A et al. Differentiated thyroid cancer, from active surveillance to advanced therapy: Toward a personalized medicine. Front Endocrinol (Lausanne) 2019;10:884
Sherman SI. Evolution of targeted therapies for thyroid carcinoma. Trans Am Clin Climatol Assoc 2019;130:255–265
Filetti S et al. ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer. Ann Oncol 2022;33(7):P674–P684
Capdevila J et al. Molecular diagnosis and targeted treatment of advanced follicular cell-derived thyroid cancer in the precision medicine era. Cancer Treat Rev 2022;106:102380
Dabrafenib highlights of prescribing information. 2022
Wirth LJ et al. Efficacy of selpercatinib in RET-altered thyroid cancers. N Engl J Med 2020;383:825–835
Josfeld L et al. Cancer patient’s perspective on shared decision-making and decision aids in oncology. J Cancer Res Clin Oncol 2021;147:1725–1732

Target Audience:

Oncologists, pathologists and other HCPs involved in the diagnosis of RET and TRK cancers, with a focus on community practitioners.

Learning Objective:


Recall thyroid RET and TRK fusion-positive cancer diagnosis and relevant genomic testing guidelines and identify ways to adapt the guidelines to local settings
Discuss “precision medicine” and new technologies, including “liquid biopsy”
Review the organisation of care and strategies for more efficient care delivery

These learning objectives are for the podcast series. This episode focuses on the first and third objective.

Funding Information:

This episode is supported by an educational grant from Eli Lilly, who have had no influence on the content or choice of faculty.

Staff Disclosure:

Dr. Matrone declares the following:

Consultant - Eli Lilly

In today’s episode, we welcome Principal Researcher Dr. David Tamborero who was integral to the development of the Molecular Tumor Board Portal to discuss the benefits associated with molecular tumor boards and the way in which the portal can support the discussions that take place at tumor board meetings, as well as how these initiatives can support the management of patients with thyroid cancer.

References


Larson KL et al. Clinical Outcomes of Molecular Tumor Boards: A Systematic Review.  
JCO Precis Oncol 2021;5:PO.20.00495
Capdevila J et al. Molecular diagnosis and targeted treatment of advanced follicular  
cell-derived thyroid cancer in the precision medicine era. Cancer Treat Rev 2022;106:102380
Mahmood U and Lorch JH. Precision Medicine in Aggressive Thyroid Cancer: Moving Beyond Multitargeted Tyrosine Kinase Inhibitors. Cancer Cytopathol 2022;130:8–11
VanderWalde A et al. Establishment of a Molecular Tumor Board (MTB) and Uptake of Recommendations in a Community Setting. J Pers Med 2020;10:252
Tamborero D et al. The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology. Nat Cancer 2022;3:251–261

Target Audience:

Oncologists, pathologists and other HCPs involved in the diagnosis of RET and TRK cancers, with a focus on community practitioners.

Learning Objective:


Recall thyroid RET and TRK fusion-positive cancer diagnosis and relevant genomic testing guidelines and identify ways to adapt the guidelines to local settings
Discuss “precision medicine” and new technologies, including “liquid biopsy”
Review the organisation of care and strategies for more efficient care delivery

These learning objectives are for the podcast series. This episode focuses on the second and third objective.

Funding Information:

This episode is supported by an educational grant from Eli Lilly, who have had no influence on the content or choice of faculty.

Staff Disclosure:

Dr. David Tamborero has no relevant disclosures to announce